Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Erlotinib + Vemurafenib |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colon cancer | sensitive | Erlotinib + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Tarceva (erlotinib) to treatment with Zelboraf (vemurafenib) inhibited viability of mouse colon cancer organoids harboring BRAF V600E in culture (PMID: 39626159). | 39626159 |
PubMed Id | Reference Title | Details |
---|---|---|
(39626159) | Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer. | Full reference... |